Betamethasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Betamethasone
- Betamethasone: From Corticosteroid-Responsive Inflammatory Conditions to Alopecia Areata
Betamethasone: From Corticosteroid-Responsive Inflammatory Conditions to Alopecia Areata
One-Sentence Summary
Betamethasone is a corticosteroid, marketed in South Africa as creams, ointments, injections, syrup and other forms. The TxGNN model predicts it may be effective for alopecia areata, an autoimmune hair-loss disease. This direction is supported by 6 registered clinical trials and 20 publications, including one completed Phase 2 randomised trial of oral betamethasone mini-pulse therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the SAHPRA licence data supplied (general use as a corticosteroid) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general glucocorticoid pharmacology, betamethasone has anti-inflammatory and immunosuppressive effects. Its efficacy in inflammatory and immune-mediated conditions is established, and mechanistically it may be applicable to alopecia areata.
Alopecia areata is an autoimmune disease in which T-cells attack the hair follicle and cause non-scarring hair loss. A corticosteroid can dampen this immune attack. Topical corticosteroids are already established agents for this disorder, and betamethasone is used clinically as a topical, intralesional and oral mini-pulse treatment. In the trials below it appears as an active arm or as the comparator.
The evidence has limits. No Phase 3 RCT is in the data, and several trials use betamethasone only as a comparator. In two trials (NCT02350023 and NCT03535233) the corticosteroid is not confirmed to be betamethasone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06786689 | Phase 2 | Completed | 60 | Weekly azathioprine pulse vs oral betamethasone mini-pulse in moderate to severe alopecia areata. This is the strongest direct evidence. |
| NCT02350023 | Phase 4 | Completed | 50 | Randomised comparison of topical latanoprost vs topical corticosteroid in localised alopecia areata. Betamethasone is likely the comparator but is not confirmed. |
| NCT05803070 | Not specified | Unknown | 59 | Topical cetirizine 1% vs betamethasone valerate 0.1% in localised alopecia areata. |
| NCT06087796 | Phase 1 | Unknown | 60 | Topical pentoxifylline 2% or metformin 10% gel vs betamethasone valerate 0.1% cream in patchy alopecia areata. |
| NCT03535233 | Phase 4 | Completed | 40 | Topical minoxidil plus potent topical corticosteroid vs intralesional corticosteroid in alopecia areata. The corticosteroid is not confirmed as betamethasone. |
| NCT01111981 | Phase 4 | Unknown | 30 | Clobetasol foam in central centrifugal cicatricial alopecia. Indirect only: a different alopecia and a different drug. |
| NCT04207931 | Phase 4 | Recruiting | 250 | Treatment outcomes in central centrifugal cicatricial alopecia. Indirect only: a scarring alopecia. |
No SANCTR or PACTR registrations were found in the data provided.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39393548 | 2025 | RCT | J Am Acad Dermatol | Microneedle transdermal delivery of compound betamethasone in alopecia areata, as an alternative to painful intralesional injection. |
| 34400956 | 2021 | RCT (double-blind, placebo-controlled) | Iran J Pharm Res | Oral betamethasone pulse (3 mg weekly), methotrexate, or the combination in 36 patients with severe alopecia areata. |
| 36257912 | 2022 | RCT (blinded, six groups) | Dermatol Ther | Latanoprost vs minoxidil, betamethasone and combinations in alopecia areata. |
| 32594786 | 2022 | RCT (within-patient) | J Dermatolog Treat | Intralesional betamethasone vs triamcinolone acetonide in localised alopecia areata. |
| 40510104 | 2025 | RCT | Cureus | Oral cyclosporine 3 mg/kg vs oral betamethasone mini-pulse in 60 patients. |
| 37870096 | 2023 | Network meta-analysis | Cochrane Database Syst Rev | Compares treatments for alopecia areata, including immunosuppressants. |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Efficacy, relapse rates and adverse effects of corticosteroid pulse therapy in alopecia areata. |
| 40519428 | 2025 | Clinical study | Cureus | Efficacy and safety of oral betamethasone mini-pulses in moderate to severe alopecia areata. |
| 38623137 | 2024 | Comparative clinical study | Cureus | Topical betamethasone dipropionate vs topical minoxidil in alopecia areata. |
| 27746635 | 2016 | Comparative study | Ann Dermatol | Oral cyclosporine vs betamethasone minipulse therapy in alopecia areata. |
The abstracts supplied were mostly truncated, so the table describes each study’s design and comparison only. Effect sizes are not reported here.
South Africa Market Information
There are 20 SAHPRA registrations in total. The main ones are listed below, and the licence data supplied do not include approved indication text. Registered forms include cream, ointment, syrup, injection, tablet, lotion and gel.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 30/13.4.1/0458 | Topivate | Cream | Not recorded |
| Reg. No. G1831 | Betnovate ‘n’ | Ointment | Not recorded |
| Reg. No. 27/21.5.1/0491 | Betanoid | Syrup | Not recorded |
| Reg. No. F/13.4.1/18 | Diprosone | Ointment | Not recorded |
| Reg. No. G2963 (Act 101/1965) | Celestone Soluspan vial 2 ml | Injection | Not recorded |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 2 RCT and several published randomised studies include betamethasone (topical, intralesional or oral mini-pulse) in alopecia areata. However, there is no Phase 3 evidence and several trials use betamethasone only as a comparator, so the evidence supports cautious progression rather than an unconditional Go.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (currently blocking, so S1 safety screening cannot proceed without them).
- Mechanism of action data from DrugBank.
- Confirmation of the corticosteroid used in NCT02350023 and NCT03535233.
- Guardrails for use:
- Limit treatment duration.
- Monitor for skin atrophy and HPA-axis suppression with topical use.
- Monitor systemic adverse effects with oral pulses.
- Counsel patients that relapse is expected after stopping.
Other predicted indications: All other predictions are on Hold and the evidence for them is weak or absent. For alopecia mucinosa, telogen effluvium, folliculitis decalvans and idiopathic steroid-sensitive nephrotic syndrome, the literature is limited to case reports, indirect studies or a single 1981 report. The remaining predictions rest on the model score alone. Sporadic idiopathic steroid-resistant nephrotic syndrome is contradictory by definition, because the condition does not respond to corticosteroids.
This report is for research reference only and does not constitute medical advice. Predicted indications require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.